Diclofenac
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Diclofenac
- Pharmacist Assessment Report
- Diclofenac: Non-steroidal anti-inflammatory drug (COX inhibitor) → hypotrichosis simplex of the scalp
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Diclofenac: Non-steroidal anti-inflammatory drug (COX inhibitor) → hypotrichosis simplex of the scalp
One-Sentence Summary
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that acts by inhibiting cyclo-oxygenase (COX) enzymes. The TxGNN model predicts it may be relevant to hypotrichosis simplex of the scalp (a hereditary hair-loss disorder), but no clinical trials and no publications in the data compiled for this report support this prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | hypotrichosis simplex of the scalp |
| TxGNN Prediction Score | 0.9969 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Diclofenac is understood to be a COX-1/COX-2 inhibitor that reduces prostaglandin-mediated pain and inflammation.
Hypotrichosis simplex of the scalp is a monogenic hair-loss disorder (for example, variants in CDSN, APCDD1 or RPL21). It is not driven by prostaglandin- or COX-mediated inflammation, so there is no clear mechanistic link to diclofenac. The only speculative angle is that COX inhibition could alter prostaglandin signalling in the hair follicle, but NSAIDs are not established hair-growth agents.
The high score is therefore best treated as a model output that has not been corroborated, not as a signal of likely benefit. It should not be taken as grounds for clinical use.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 1299J | Fenac EC | Tablet (enteric coated) containing diclofenac sodium 25 mg | Not recorded in the local data |
Safety Considerations
- Drug Interactions: The interaction screen was completed and returned 100 recorded interactions. The entries listed are mostly of Moderate or Minor severity. Examples of Moderate interactions include:
- Corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide)
- Aspirin (acetylsalicylic acid)
- Mesalazine and balsalazide
- Antidiabetic agents (metformin, glimepiride, glipizide, chlorpropamide, acetohexamide, exenatide)
- Aprepitant
- Fenfluramine and dexfenfluramine
Minor interactions include the H2 blockers famotidine, ranitidine and cimetidine.
Beyond this, please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or publications, and there is no plausible mechanistic link between COX inhibition and this genetic hair-loss disorder. Evidence remains at model-prediction level only (L5).
To proceed, the following is needed:
- Preclinical or mechanistic evidence that prostaglandin/COX signalling is relevant to hypotrichosis simplex of the scalp
- Detailed mechanism of action data for diclofenac
- A review of the TGA-approved Product Information for safety, warnings and contraindications
- Any registered clinical or observational studies in this condition before further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.